Health Technology Assessment Reports for Non-Oncology Medications in Canada from 2018 to 2022: Methodological Critiques on Manufacturers’ Submissions and a Comparison between Manufacturer and Canadian Agency for Drugs and Technologies in Health (CADT
There was high frequency of CADTH critiques on manufacturers' submissions in all four aspects of economic submissions: effectiveness, cost, utility score and structure. We observed a higher median incremental cost and lower median incremental QALYs in the CADTH reanalysis compared with the manufacturers' submissions. The resulting higher ICUR in the CADTH reanalysis often leads to a recommendation that the manufacturer needs to reduce its price. The 3-year budget impact was higher in the CADTH reanalyses compared with manufacturers' submissions.
Authors
- Mitchell Levine (ORCID: https://orcid.org/0000-0002-9010-0886)
- Behnam Sadeghirad (ORCID: https://orcid.org/0000-0001-9422-5232)
- Fatemeh Mirzayeh Fashami (ORCID: https://orcid.org/0000-0003-0189-9065)
- Jean‐Éric Tarride (ORCID: https://orcid.org/0000-0003-2913-7580)
- Kimia Hariri (ORCID: https://orcid.org/0000-0002-1071-5515)
- Amirreza Peyrovinasab (ORCID: https://orcid.org/0009-0004-6100-3667)
Institutions
- Islamic Azad University Medical Branch of Tehran (IR)
- McMaster University Medical Centre (CA)
- Impact (CA)
- St. Joseph’s Healthcare Hamilton (CA)
- Mazandaran University of Medical Sciences (IR)
- McMaster University (CA)
Publication Details
- Journal
- PharmacoEconomics - Open
- Published
- 2024-08-05
- DOI
- https://doi.org/10.1007/s41669-024-00511-9
- Citations
- 2
- Primary Topic
- Health Systems, Economic Evaluations, Quality of Life
- Type
- article
- Field-Weighted Citation Impact
- 2.26